Mar 2, 2017

Icahn cuts regulation — and saves own company $200M

Bread for the World / AP

Carl Icahn, Donald Trump's special advisor for deregulatory efforts, has successfully pushed the ethanol lobby to adopt a regulatory change that it opposed, but which will save his refinery company more than $200 million annually, according to The Intercept.

The renewable fuel standard will now require wholesalers — instead of refiners — to produce gasoline with a minimum volume of renewable sources. The previous regulation cost Icahn's company, CVR Energy, millions last year since it doesn't have the capabilities to blend ethanol to meet the minimum, and instead had to buy renewable fuel credits.

Ethanol companies protested the draft language of an executive order on the subject, saying it would cost consumers money and render the renewable fuels market volatile.

  • The Renewable Fuels Association expressed "continued opposition" to the change
  • Jeff Broin of the nation's largest ethanol producer, Poet, called it a "back-room deal"
  • Emily Skor of Growth Energy said the change only benefits Icahn
  • Both Republican senators from Iowa (the nation's leading biofuel state) oppose the change, and Amy Klobuchar of Minnesota said Icahn's role deserves "serious scrutiny"

The compromise: The biofuel lobby was told blends with 15 percent ethanol would be sold year-round instead of just during certain seasons as they are now, but the White House has not yet committed to that change, Bloomberg reports.

Go deeper

In photos: Trump visits Taj Mahal after massive rally in India

President Trump and First Lady Melania Trump at the Taj Mahal. Photo: Mandel Ngan/AFP via Getty Images

President Trump visited India's Taj Mahal on Monday, hours after telling a massive crowd at a rally in Ahmedabad that he hopes to reach a trade deal with his "true friend" Prime Minister Narendra Modi during his two-day visit to the country.

Why it matters: The countries are forging deeper ties as India’s location, size and economic growth make it the "obvious counterweight to China" for American policymakers.

Go deeperArrowUpdated 9 mins ago - World

Coronavirus stress tests drug industry's dependence on China

A Hong Kong commuter wears a face mask. Photo: Miguel Candela/SOPA Images/LightRocket via Getty Images

It's unclear whether the rapid spread of the novel coronavirus will actually result in prescription drug shortages, but it has undoubtedly highlighted the potential vulnerabilities of having the supply chain for American drugs so dependent on China.

Driving the news: About 150 prescription drugs — including antibiotics, generics and some branded drugs without alternatives — are at risk of shortage if the coronavirus outbreak in China worsens, per two sources familiar with a list of at-risk drugs compiled by the Food and Drug Administration.

Bernie's path to the presidency

Sen. Bernie Sanders speaks yesterday during a rally at Houston University. Photo: Mark Felix/AFP via Getty Images

Lots of Democrats are in full panic that Bernie Sanders will win the nomination and get clobbered in the general election — and bring the party down, too. But the evidence, particularly the polling, doesn't back those doomsday warnings.

Why it matters: Virtually every national and swing state poll shows Sanders tied with or beating President Trump.  And, unlike every rival, he has a huge base of fervent, unshakable supporters he can only grow.